COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00384150
Recruitment Status : Terminated (Enrollment challenges due to changes in standards of care resulted in premature termination. No safety or efficacy events factored into this action.)
First Posted : October 5, 2006
Last Update Posted : November 26, 2015
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : January 2010
Actual Study Completion Date : January 2010
Certification/Extension First Submitted : October 30, 2015